Amir Shmueli1, Hamutal Meiri, Ron Gonen. 1. Department of Health Management and Economics, Braun School of Public Health, The Hebrew University-Hadassah, Israel..
Abstract
BACKGROUND: Pre-eclampsia is a major contributor to maternal and neonatal morbidity and mortality. Our objectives in this study are to economically assess, from the payer perspective, routine screening for pre-eclampsia using placental markers -placental protein 13 and placental growth factor - and uterine artery Doppler compared with standard care. METHODS: A decision model was developed, which progresses through three sequential endpoints, and compares screening with no screening: (1) Pre-eclampsia yes/no: calculation of the incremental cost of pre-eclampsia-case averted; (2) Hospital discharge: calculation of the mean accumulated costs until discharge after delivery; and (3) Offspring death: calculation of the incremental cost per quality of life-adjusted life-year gained by screening. Data used includes: (1) Obstetrical data of 14 500 births; (2) cost data from the Israeli Ministry of Health and the literature; and (3) screening performance and outcome from the literature. RESULTS: (1) The incremental cost of pre-eclampsia-case averted is $66,949 and $24,723 when the prevalence is 1.7 and 5% respectively. (2) With test cost of $112, the total cost until discharge with/without screening is equal. With pre-eclampsia prevalence of 3%, screening is cheaper. (3) The cost per quality of life-adjusted life-year with screening is $18,919 and < $10,000 with pre-eclampsia prevalence of 1.7 and 3%, respectively. CONCLUSIONS: Screening for pre-eclampsia is cost-effective under various scenarios.
BACKGROUND: Pre-eclampsia is a major contributor to maternal and neonatal morbidity and mortality. Our objectives in this study are to economically assess, from the payer perspective, routine screening for pre-eclampsia using placental markers -placental protein 13 and placental growth factor - and uterine artery Doppler compared with standard care. METHODS: A decision model was developed, which progresses through three sequential endpoints, and compares screening with no screening: (1) Pre-eclampsia yes/no: calculation of the incremental cost of pre-eclampsia-case averted; (2) Hospital discharge: calculation of the mean accumulated costs until discharge after delivery; and (3) Offspring death: calculation of the incremental cost per quality of life-adjusted life-year gained by screening. Data used includes: (1) Obstetrical data of 14 500 births; (2) cost data from the Israeli Ministry of Health and the literature; and (3) screening performance and outcome from the literature. RESULTS: (1) The incremental cost of pre-eclampsia-case averted is $66,949 and $24,723 when the prevalence is 1.7 and 5% respectively. (2) With test cost of $112, the total cost until discharge with/without screening is equal. With pre-eclampsia prevalence of 3%, screening is cheaper. (3) The cost per quality of life-adjusted life-year with screening is $18,919 and < $10,000 with pre-eclampsia prevalence of 1.7 and 3%, respectively. CONCLUSIONS: Screening for pre-eclampsia is cost-effective under various scenarios.
Authors: Liona C Poon; Andrew Shennan; Jonathan A Hyett; Anil Kapur; Eran Hadar; Hema Divakar; Fionnuala McAuliffe; Fabricio da Silva Costa; Peter von Dadelszen; Harold David McIntyre; Anne B Kihara; Gian Carlo Di Renzo; Roberto Romero; Mary D'Alton; Vincenzo Berghella; Kypros H Nicolaides; Moshe Hod Journal: Int J Gynaecol Obstet Date: 2019-05 Impact factor: 3.561
Authors: Jeffrey N Bone; Asif R Khowaja; Marianne Vidler; Beth A Payne; Mrutyunjaya B Bellad; Shivaprasad S Goudar; Ashalata A Mallapur; Khatia Munguambe; Rahat N Qureshi; Charfudin Sacoor; Esperanca Sevene; Geert W J Frederix; Zulfiqar A Bhutta; Craig Mitton; Laura A Magee; Peter von Dadelszen Journal: BMJ Glob Health Date: 2021-05
Authors: Asif R Khowaja; Craig Mitton; Stirling Bryan; Laura A Magee; Zulfiqar A Bhutta; Peter von Dadelszen Journal: Implement Sci Date: 2015-05-26 Impact factor: 7.327
Authors: Åsa Nääv; Lena Erlandsson; Josefin Axelsson; Irene Larsson; Martin Johansson; Lena Wester-Rosenlöf; Matthias Mörgelin; Vera Casslén; Magnus Gram; Bo Åkerström; Stefan R Hansson Journal: PLoS One Date: 2015-05-08 Impact factor: 3.240
Authors: Zoë M McLaren; Alana Sharp; John P Hessburg; Amir Sabet Sarvestani; Ethan Parker; James Akazili; Timothy R B Johnson; Kathleen H Sienko Journal: Dev Eng Date: 2017-07-03